Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$256.27
-1.5%		$254.66
$190.75
▼
$267.47
$453.11B0.294.28 million shs4.73 million shs
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$108.29
-0.5%		$104.43
$81.97
▼
$137.49
$187.45B0.597.45 million shs7.02 million shs
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.96
-1.3%		$9.75
$6.00
▼
$11.22
$2.55B0.573.01 million shs1.48 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,147.06
-1.1%		$1,191.71
$712.05
▼
$1,292.65
$1.08T0.52.54 million shs2.22 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$145.55
-2.2%		$85.75
$22.28
▼
$176.66
$58.11B1.133.06 million shs14.93 million shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$35.25
-1.1%		$34.78
$20.65
▼
$38.13
$2.31B-2.33662,872 shs483,574 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+0.07%+5.18%+12.56%+21.12%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.00%-3.85%+0.40%+18.74%-17.97%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
0.00%+1.43%+7.10%+18.43%+20.14%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-1.88%-3.76%+1.23%+55.79%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+5.48%+170.24%+206.81%+505.20%
Pharvaris N.V. stock logo
PHVS
Pharvaris
0.00%-0.20%+2.32%+13.38%+60.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$256.27
-1.5%		$254.66
$190.75
▼
$267.47
$453.11B0.294.28 million shs4.73 million shs
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$108.29
-0.5%		$104.43
$81.97
▼
$137.49
$187.45B0.597.45 million shs7.02 million shs
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.96
-1.3%		$9.75
$6.00
▼
$11.22
$2.55B0.573.01 million shs1.48 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,147.06
-1.1%		$1,191.71
$712.05
▼
$1,292.65
$1.08T0.52.54 million shs2.22 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$145.55
-2.2%		$85.75
$22.28
▼
$176.66
$58.11B1.133.06 million shs14.93 million shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$35.25
-1.1%		$34.78
$20.65
▼
$38.13
$2.31B-2.33662,872 shs483,574 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+0.07%+5.18%+12.56%+21.12%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.00%-3.85%+0.40%+18.74%-17.97%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
0.00%+1.43%+7.10%+18.43%+20.14%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-1.88%-3.76%+1.23%+55.79%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+5.48%+170.24%+206.81%+505.20%
Pharvaris N.V. stock logo
PHVS
Pharvaris
0.00%-0.20%+2.32%+13.38%+60.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.88
Moderate Buy$275.957.68% Upside
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.96
Moderate Buy$119.5010.35% Upside
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.67
Moderate Buy$20.60106.83% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,292.1812.65% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$76.72-47.29% Downside
Pharvaris N.V. stock logo
PHVS
Pharvaris
2.86
Moderate Buy$51.0844.90% Upside

Current Analyst Ratings Breakdown

Latest MRNA, ABT, ABBV, BCRX, LLY, and PHVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$40.00 ➝ $81.00
9/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform ➝ Buy
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Bradesco Corretora logo
Bradesco Corretora
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$180.00
8/27/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
8/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B7.40$15.14 per share16.93($3.33) per share-76.96
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$46.59B4.02$6.99 per share15.50$29.91 per share3.62
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$874.84M2.91$1.24 per share8.04($1.78) per share-5.60
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$79.67B13.55$25.09 per share45.72$35.99 per share31.87
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B29.89N/AN/A$16.93 per share8.60
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$5.35 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5472.3915.871.169.80%-422.07%14.34%10/30/2026 (Estimated)
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$6.52B$3.0935.0517.812.0111.65%17.69%9.44%10/21/2026 (Estimated)
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$263.86M-$1.50N/A13.83N/A-40.90%-86.89%66.37%11/2/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$29.8038.4924.971.4233.53%97.83%23.23%10/29/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$198.79M-$3.05N/AN/AN/AN/A-61.40%-56.00%11/11/2026 (Estimated)

Latest MRNA, ABT, ABBV, BCRX, LLY, and PHVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.7467-$0.81-$0.0633-$0.80N/AN/A
8/5/2026Q2 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.1542$0.30+$0.1458$0.30$183.28 million$218.25 million
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.61$3.65+$0.04$2.03$16.80 billion$16.99 billion
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/16/2026Q2 2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.28$1.31+$0.03$0.53$12.52 billion$12.59 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.70%+6.80%195.48%53 Years
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.522.33%+10.39%81.55%54 Years
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.60%+15.18%23.22%11 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A

Latest MRNA, ABT, ABBV, BCRX, LLY, and PHVS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.59%8/14/20268/14/20269/10/2026
6/12/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.632.82%7/15/20267/15/20268/17/2026
6/18/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.83%7/15/20267/15/20268/14/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.57
1.38
0.97
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.32
2.29
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.41
1.35
1.00
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
11.94
11.94

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.80%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Pharvaris N.V. stock logo
PHVS
Pharvaris
11.84%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.73 billion1.72 billionOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
530255.54 million245.83 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.36 million940.04 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Pharvaris N.V. stock logo
PHVS
Pharvaris
3065.41 million57.66 millionNot Optionable

Recent News About These Companies

Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It (PHVS)
...
 |  marketbeat.comhttps://www.marketbeat.com/articles/moderna-just-doubled-overnight-and-2-more-healthcare-stocks-could-follow-it/
Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Moderate Buy" by Analysts
September 4 at 4:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-pharvaris-nv-nasdaq-phvs-given-consensus-recommendation-of-moderate-buy-by-analysts-2026-09-04/
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
September 3 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355738/0/en/pharvaris-presents-translational-nonclinical-and-clinical-data-at-bradykinin-symposium-2026.html
Pharvaris N.V. $PHVS Shares Purchased by Wellington Management Group LLP
September 3 at 4:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pharvaris-nv-phvs-shares-purchased-by-wellington-management-group-llp-2026-09-03/
BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVS
September 3 at 3:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-makes-new-investment-in-pharvaris-nv-phvs-2026-09-03/
Pharvaris N.V. (NASDAQ:PHVS) Short Interest Up 48.7% in August
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-pharvaris-nv-nasdaq-phvs-short-interest-up-487-in-august-2026-09-01/
Moore Capital Management LP Buys Shares of 44,001 Pharvaris N.V. $PHVS
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-moore-capital-management-lp-buys-shares-of-44001-pharvaris-nv-phvs-2026-09-01/
Alyeska Investment Group L.P. Purchases 281,829 Shares of Pharvaris N.V. $PHVS
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-alyeska-investment-group-lp-purchases-281829-shares-of-pharvaris-nv-phvs-2026-09-01/
Deutsche Bank AG Purchases Shares of 53,469 Pharvaris N.V. $PHVS
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-purchases-shares-of-53469-pharvaris-nv-phvs-2026-08-29/
venBio Partners LLC Invests $160.57 Billion in Pharvaris N.V. $PHVS
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-venbio-partners-llc-invests-16057-billion-in-pharvaris-nv-phvs-2026-08-28/
Seven Fleet Capital Management LP Buys 457,804 Shares of Pharvaris N.V. $PHVS
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-buys-457804-shares-of-pharvaris-nv-phvs-2026-08-27/
525,750 Shares in Pharvaris N.V. $PHVS Purchased by Elmind Capital LP
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-525750-shares-in-pharvaris-nv-phvs-purchased-by-elmind-capital-lp-2026-08-26/
5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVS
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-5am-venture-management-llc-makes-new-2758-billion-investment-in-pharvaris-nv-phvs-2026-08-26/
105,528 Shares in Pharvaris N.V. $PHVS Purchased by ADAR1 Capital Management LLC
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-105528-shares-in-pharvaris-nv-phvs-purchased-by-adar1-capital-management-llc-2026-08-26/
Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - What's Next?
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-pharvaris-nasdaq-phvs-sees-strong-trading-volume-whats-next-2026-08-25/
Pharvaris (NASDAQ:PHVS) Hits New 12-Month High - What's Next?
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pharvaris-nasdaqphvs-hits-new-12-month-high-whats-next-2026-08-21/
Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares of Stock
August 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-phvs-insider-buying-and-selling-2026-08-19/
Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-pharvaris-nasdaqphvs-ceo-sells-2292-shares-2026-08-18/
What is HC Wainwright's Forecast for Pharvaris Q3 Earnings?
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-forecast-for-pharvaris-q3-earnings-2026-08-18/
Research Analysts Issue Forecasts for Pharvaris Q4 Earnings
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/research-analysts-issue-forecasts-for-pharvaris-q4-earnings-2026-08-17/
Pharvaris (PHVS) Gets a Hold from Bank of America Securities
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3848620/pharvaris-phvs-gets-a-hold-from-bank-of-america-securities/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
Trading floor with digital stock displays and workstations, overlaid with the text "S&P 500".
5 Reasons the S&P 500 Could Keep Rallying Through Year-End
By Thomas Hughes | August 20, 2026
Illustration of an upward-trending stock chart line overlaid on a city skyline of office towers at sunset.
Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
By Nathan Reiff | August 30, 2026
Moderna logo displayed in a laboratory setting with a vaccine vial, petri dishes, and a microscope.
Moderna’s 177% Surge Has Investors Asking What Comes Next
By Sam Quirke | August 21, 2026
AbbVie stock logo

AbbVie NYSE:ABBV

$256.27 -3.94 (-1.51%)
As of 09/4/2026 03:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$108.29 -0.50 (-0.46%)
As of 09/4/2026 03:58 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.96 -0.13 (-1.29%)
As of 09/4/2026 04:00 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,147.06 -12.54 (-1.08%)
As of 09/4/2026 03:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Moderna stock logo

Moderna NASDAQ:MRNA

$145.55 -3.32 (-2.23%)
As of 09/4/2026 04:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$35.25 -0.41 (-1.15%)
As of 09/4/2026 04:00 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas